{"gene":"CCL3","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1995,"finding":"CCL3 (MIP-1α), along with RANTES and MIP-1β, was identified as a major HIV-suppressive factor produced by CD8+ T cells. Purified proteins from CD8+ T cell supernatants showed sequence identity with RANTES and MIP-1α; neutralizing antibody combinations against all three chemokines completely blocked HIV-SF activity; recombinant CCL3 caused dose-dependent inhibition of HIV-1, HIV-2, and SIV replication.","method":"Protein purification from cell supernatants, sequence identity, neutralizing antibody blockade, recombinant protein inhibition assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (purification, sequencing, neutralizing antibody combination blockade, recombinant protein assay); widely replicated and highly cited","pmids":["8525373"],"is_preprint":false},{"year":1995,"finding":"MIP-1α (CCL3) is required in vivo for a normal inflammatory response to viral infection. CCL3-knockout mice were resistant to Coxsackievirus-induced myocarditis and showed reduced pneumonitis and delayed clearance of influenza virus, with no overt hematopoietic abnormalities.","method":"Gene knockout mouse model (MIP-1α -/- mice), viral infection models (Coxsackievirus, influenza), histological and virological assessment","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined phenotypic readout across two viral models, replicated finding","pmids":["7667639"],"is_preprint":false},{"year":1993,"finding":"HM145 (later identified as CCR1) is a functional G protein-coupled receptor for LD78 (CCL3), as demonstrated by decreased cAMP accumulation and calcium influx in stable transfectants expressing HM145 upon LD78 stimulation.","method":"Stable transfection, cAMP accumulation assay, calcium influx measurement","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — functional receptor identification via two orthogonal second-messenger readouts in stable transfectants","pmids":["7505609"],"is_preprint":false},{"year":2010,"finding":"CCL3 (MIP-1α) and CCL4 (MIP-1β) form rod-shaped, double-helical polymers via a polymerization process. Polymerization buries receptor-binding sites of CCL3, so depolymerization mutations enhance CCL3's ability to arrest monocytes on activated endothelium. Insulin-degrading enzyme (IDE) selectively degrades monomeric CCL3, and decreased IDE expression leads to elevated CCL3 in microglial cells.","method":"X-ray crystallography, biophysical analysis (SEC, AUC), mathematical modelling, mutagenesis, monocyte arrest assay, proteomics, IDE knockdown in microglial cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mutagenesis and multiple orthogonal biophysical/functional validations in one study","pmids":["20959807"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of CCL3 oligomers bound to glycosaminoglycans (GAGs) revealed that CCL3 forms rod-shaped double-helical oligomers and uses a distinct GAG-binding groove formed by residues from two partially buried BBXB motifs. An alternative CCL3 oligomer structure showed that conformational changes in the N-termini profoundly alter surface properties and dimer-dimer interactions, affecting both GAG binding and oligomerization.","method":"X-ray crystallography, biophysical analyses, mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of GAG-bound CCL3 oligomers with structural and mutagenic validation","pmids":["27091995"],"is_preprint":false},{"year":1999,"finding":"LD78β (MIP-1αP), a non-allelic isoform of CCL3 (LD78α), has ~6-fold enhanced binding affinity to CCR5 and ~15–20-fold enhanced affinity to the D6 receptor compared to LD78α. A proline residue at position 2 of LD78β is responsible for this enhanced receptor binding activity and markedly higher HIV-1 suppressive activity.","method":"Receptor binding affinity assays, site-directed mutagenesis (Pro-2 substitution), HIV-1 suppression assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis identifying specific residue + receptor binding + functional HIV suppression assays","pmids":["10364178"],"is_preprint":false},{"year":2005,"finding":"Neutrophil-derived serine proteases (cathepsin G, elastase, proteinase 3) cleave CCL3 isoforms LD78β and LD78α at specific sites (Thr16-Ser17, Phe24-Ile25, Tyr28-Phe29, Thr31-Ser32), with cathepsin G preferentially cleaving at Phe24-Ile25 and Tyr28-Phe29 and elastase/proteinase 3 at Thr16-Ser17 and Thr31-Ser32. Proteolysis of LD78β results in loss of chemotactic activity.","method":"In vitro protease cleavage assay, mass spectrometry and peptide sequencing, serine protease inhibitor studies, neutrophil lysates from Papillon-Lefèvre syndrome patients, chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro cleavage with MS/sequencing to define sites, mutant patient cell validation, functional loss demonstrated","pmids":["15728180"],"is_preprint":false},{"year":1993,"finding":"The LD78α gene promoter contains multiple positive and negative regulatory elements. A negative regulatory element (ICK-1) is a binding site for both positive (ICK-1B) and negative (ICK-1A) transcriptional factors; an ICK-1-like element is shared with IL-3 and GM-CSF gene promoters, suggesting common transcriptional control among hematopoietic growth factors.","method":"Promoter deletion analysis, electrophoretic mobility shift assay (EMSA), in vivo footprinting, transfection/reporter assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and reporter assays defining specific regulatory elements; single-lab study","pmids":["8474441"],"is_preprint":false},{"year":2004,"finding":"PGE2 inhibits CCL3 and CCL4 expression in dendritic cells via a novel signaling pathway: EP-2 → cAMP → EPAC → PI3-kinase → PKB → GSK-3, leading to increased DNA binding of the CCAAT displacement protein (CDP), a transcriptional repressor; CDP knockdown with siRNA directly linked CDP to CCL3/4 transcription.","method":"Pharmacological inhibitors of each pathway step, siRNA knockdown of CDP, EMSA/DNA binding assays, ELISA for CCL3/4 protein","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors combined with siRNA knockdown establishing direct transcriptional link; single lab","pmids":["15498767"],"is_preprint":false},{"year":2011,"finding":"Tristetraprolin (TTP) directly binds CCL3 mRNA via conserved AU-rich elements and destabilizes it. TTP-/- macrophages produce elevated LPS-induced CCL3; CCL3-/-/TTP-/- double knockout mice show significant improvement in inflammatory arthritis and reduced aortic plaque formation compared with TTP-/- single knockouts.","method":"TTP-bound mRNA screen in activated macrophages, RIP/RNA binding assay, TTP-/- and CCL3-/-/TTP-/- double-KO mice, histological and functional assessments","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct RNA-binding identification plus genetic epistasis via double-KO rescuing multiple in vivo disease phenotypes","pmids":["21784977"],"is_preprint":false},{"year":2002,"finding":"CCL3 (MIP-1α) acts as a growth, survival, and chemotactic factor in multiple myeloma (MM) cells by activating both the AKT/PKB and the MAPK/ERK pathways; PI3-K inhibitors blocked AKT activation but not ERK activation, indicating no cross-talk between these two CCL3-dependent signaling branches in MM cells.","method":"Chemotaxis assay, cell proliferation/survival assays, pathway inhibitors (PI3-K inhibitors), Western blot for pAKT and pERK","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays and pharmacological dissection of signaling branches; single lab","pmids":["12506012"],"is_preprint":false},{"year":2008,"finding":"The CCL3-CCR5 axis regulates intratumoral accumulation of macrophages, granulocytes, and fibroblasts and promotes neovascularization in lung metastasis. CCL3 stimulates macrophages to express MMP-9 and fibroblasts to express HGF via CCR5. CCL3-/- and CCR5-/- mice showed markedly reduced lung metastasis foci, reduced intratumoral leukocyte/fibroblast accumulation, and reduced MMP-9 and HGF expression.","method":"CCL3-/- and CCR5-/- mice, bone marrow chimera, in vitro CCL3 stimulation assays, immunohistochemistry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — dual-gene KO with chimeric mouse models and in vitro mechanistic validation; multiple readouts","pmids":["18941229"],"is_preprint":false},{"year":2010,"finding":"CCL3 (MIP-1α) released by activated endothelial cells binds preferentially to the apical surface of cytokine-activated human brain microvessel endothelial cells (HBMEC). In resting HBMEC, CCL3 is minimally expressed, but TNF-α, IL-1β, LPS and TNF-α/IFN-γ significantly upregulate its expression and release; the polarized apical surface presentation of CCL3 after cytokine treatment was established by immunoelectron microscopy.","method":"Primary HBMEC culture, ELISA, immunocytochemistry, immunoelectron microscopy","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct localization by immunoelectron microscopy with cytokine induction; single lab","pmids":["20047691"],"is_preprint":false},{"year":2006,"finding":"CCL3 (MIP-1α) expression is downstream of FGFR3 and RAS-MAPK signaling in multiple myeloma. FGFR3 inhibitors and FGFR3-specific siRNA downregulated MIP-1α promoter activity, gene expression, and protein secretion; ERK1 inhibition also downregulated MIP-1α in cells with RAS mutations, placing CCL3 downstream of FGFR3→RAS→MAPK.","method":"FGFR3 kinase inhibitors, FGFR3 siRNA, FGF ligand stimulation, promoter assays, gene expression profiling, ERK1 inhibition","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (3 inhibitors + siRNA + ligand stimulation) defining pathway position; single lab","pmids":["16849642"],"is_preprint":false},{"year":2004,"finding":"CCL3 (MIP-1α) and its receptor CCR1 are required for hepatocellular carcinoma progression. CCR1- and CCL3-deficient mice showed markedly reduced tumor foci and reduced tumor angiogenesis, associated with decreased intratumoral Kupffer cell accumulation and reduced MMP-9 gene expression.","method":"CCR1-/- and CCL3-/- mice in DEN-induced and HBs antigen splenocyte transfer HCC models, immunohistochemistry, gene expression analysis","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two-gene KO in two independent HCC models with multiple readouts; single lab","pmids":["16284949"],"is_preprint":false},{"year":2010,"finding":"CCL3 (via CCR1) mediates the thoracic radiation-induced lung inflammation and fibrosis. Irradiated CCL3-/- mice or CCR1-/- mice did not develop lung inflammation, fibrosis, or decline in lung function seen in wild-type mice; pharmacologic CCR1 inhibition also prevented these outcomes. By contrast, CCR5-/- mice were not protected.","method":"CCL3-/-, CCR1-/-, CCR5-/- mice, pharmacological CCR1 inhibitor, hydroxyproline assay, flow cytometry, lung function measurement","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic dissection with three KO lines plus pharmacological confirmation, selective for CCR1 over CCR5","pmids":["20870892"],"is_preprint":false},{"year":2004,"finding":"CCL3 deficiency (MIP-1α-/-) attenuates T cell-mediated hepatitis by reducing recruitment of CCR1-expressing CD4+ T cells to the liver, with consequent reduction in hepatic IFN-γ production. Pharmacological dual CCR1/CCR5 blockade with met-RANTES also reduced hepatic injury and CD4+ T cell liver infiltration.","method":"CCL3-/- mice, con A hepatitis model, flow cytometry, met-RANTES pharmacological blockade, biochemical and histological liver injury assessment","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mice combined with pharmacological blockade defining CCL3-CCR1 pathway in T cell hepatitis","pmids":["15368307"],"is_preprint":false},{"year":2008,"finding":"CCL3 selectively mobilizes mature NK (mNK) cells from the bone marrow into the periphery by acting through CCR1, and inhibits CXCL12-mediated mNK cell retention in vitro. pNK cells migrate to CCL3 only after CXCL12 priming, while immature NK cells (iNK) lack CCR1 and do not respond to CCL3.","method":"Mouse bone marrow NK cell subset characterization, in vitro chemotaxis assays, in vivo CCL3 and CXCR4 antagonist (AMD-3100) administration, flow cytometry","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro combination; single lab","pmids":["18227348"],"is_preprint":false},{"year":1992,"finding":"CCL3/SCI/MIP-1α inhibits proliferation of primitive hematopoietic stem cell progenitors (CFU-S day 12 and day 8) in vitro in a dose-dependent manner and reduces CFU-S compartment cycling in vivo, providing myeloprotection after chemotherapy as shown by improved neutrophil recovery kinetics.","method":"In vitro CFU-S colony-forming assay, in vivo mouse bone marrow regeneration models, neutrophil recovery kinetics","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro dose-response plus in vivo myeloprotection models with functional neutrophil recovery endpoint; replicated by multiple labs","pmids":["1571537"],"is_preprint":false},{"year":1993,"finding":"Recombinant LD78 protein in solution forms soluble heterogeneous multimeric complexes (100–>250 kDa) from an 8-kDa monomer; defined homogeneous monomer and tetramer forms can be prepared and display distinct conformational properties, as determined by analytical ultracentrifugation, circular dichroism, and fluorescence spectroscopy.","method":"Analytical ultracentrifugation, circular dichroism, fluorescence spectroscopy","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — biophysical characterization of oligomeric states with multiple methods but in single study","pmids":["8499450"],"is_preprint":false},{"year":1992,"finding":"MIP-1α (LD78/SCI) inhibits proliferation of clonogenic epidermal keratinocytes in vitro, and MIP-1α mRNA is present in epidermal Langerhans cells but not in keratinocytes, suggesting a paracrine growth inhibitory role in keratopoiesis.","method":"In vitro clonogenic keratinocyte proliferation assay with recombinant MIP-1α, Northern blot/in situ hybridization for mRNA localization","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — in vitro inhibition assay plus cell-type-specific mRNA localization; single lab","pmids":["8345211"],"is_preprint":false},{"year":1994,"finding":"MIP-1α modulates spermatogenesis stage-specifically: it increases DNA synthesis in primitive type A2-4 spermatogonia and premeiotic cells, while inhibiting DNA synthesis in more differentiated intermediate and type B spermatogonia. An anti-MIP-1α antibody cross-reacts with a 15 kDa protein expressed at every spermatogenic stage.","method":"In vitro stage-specific DNA synthesis assay with recombinant MIP-1α, immunohistochemistry with anti-MIP-1α antibody","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vitro functional assay + immunolocalization; single lab, single study","pmids":["8187954"],"is_preprint":false},{"year":1997,"finding":"MIP-1α (LD78) promotes osteoclastogenesis on calcified matrices in the absence of osteotropic hormones and is expressed by osteoblasts at bone-remodeling sites and eosinophilic myelocytes in human bone marrow, suggesting a role in bone remodeling.","method":"In situ hybridization, immunohistochemistry with monoclonal antibody, in vitro osteoclastogenesis on calcified matrices","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — in vitro osteoclastogenesis assay plus direct localization; single lab","pmids":["9121122"],"is_preprint":false},{"year":2013,"finding":"In EBV-infected B cells (LCLs), LMP1-mediated JNK activation is responsible for upregulation of CCL3 and CCL4. Autocrine CCL3 and CCL4 are required for LCL survival and proliferation, as shRNA knockdown or neutralizing antibodies against CCL3/CCL4 suppressed cell proliferation and induced apoptosis.","method":"Cytokine antibody arrays, JNK inhibitor, shRNA knockdown, neutralizing antibodies, apoptosis assays","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway defined via inhibitor plus shRNA/antibody intervention with functional survival readout; single lab","pmids":["23760235"],"is_preprint":false},{"year":2016,"finding":"CCL3 promotes VEGF-A expression in osteosarcoma cells via activation of JNK, ERK, and p38 MAPK pathways, with each pathway inhibitor abolishing CCL3-induced VEGF-A upregulation. CCL3 also reduces miR-374b expression, and miR-374b mimic reverses CCL3-promoted VEGF-A expression and angiogenesis in vitro and in vivo.","method":"Kinase inhibitors (JNK, ERK, p38), miR-374b mimic transfection, endothelial progenitor cell migration/tube formation assays, mouse xenograft model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — multiple pathway inhibitors plus miRNA rescue experiment with in vitro and in vivo validation; single lab","pmids":["26713602"],"is_preprint":false},{"year":2016,"finding":"Elevated CCL3 in the leukemic environment suppresses erythropoiesis via CCR1-mediated p38 phosphorylation and subsequent GATA1 downregulation. CCR1 antagonist partially recovered erythroid colony yield; knockdown of CCL3 attenuated leukemic progression and alleviated anemia.","method":"Cytokine array, colony-forming cell assay, CCR1 antagonist, Western blot for p38/GATA1, CCL3 knockdown in AML mouse model","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic signaling dissection (CCR1→p38→GATA1) with pharmacological and genetic perturbation; single lab","pmids":["27109512"],"is_preprint":false},{"year":2009,"finding":"Intracerebroventricularly administered CCL3 (MIP-1α) induces fever that is independent of LPS signaling cascade (PFPF, ET-1) but is dependent on CRF: a non-selective CRF receptor antagonist (α-helical CRF9-41) reduced CCL3-induced fever, while bosentan (ET receptor antagonist) did not. Anti-CCL3 antibody abolished CCL3-induced fever but did not affect LPS-induced fever.","method":"Intracerebroventricular injection, pharmacological antagonists (anti-CCL3 antibody, bosentan, α-helical CRF9-41), temperature measurement in rats","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection defining CCL3 pyrogenic mechanism; single lab, single study","pmids":["19285486"],"is_preprint":false},{"year":2013,"finding":"CCL3 stimulates human chondrosarcoma cell migration and MMP-2 expression via CCR5, AMPK, p38 MAPK, and NF-κB signaling pathways. Inhibitors or inactive mutants of AMPK, p38, and NF-κB abolished CCL3-induced MMP-2 expression and migration; MMP-2 siRNA or inhibitor blocked CCL3-induced migration.","method":"CCR5 knockdown, pharmacological inhibitors and dominant-negative mutants of AMPK/p38/NF-κB, MMP-2 siRNA, migration assay","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors + siRNA; single lab","pmids":["24047437"],"is_preprint":false},{"year":2018,"finding":"CCL3-/- mice exhibit loss of mature myeloid populations in peripheral blood while myeloid progenitors and HSPCs are increased, with unchanged bone marrow microenvironmental cell populations. This demonstrates that CCL3 promotes myeloid lineage differentiation and regulates HSPC pool size independently of the bone marrow microenvironment.","method":"CCL3-/- mice, flow cytometry of hematopoietic compartments, bone marrow microenvironment analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO phenotype with defined cellular readouts; single lab","pmids":["30279500"],"is_preprint":false},{"year":2022,"finding":"Docetaxel (DTX) induces CCL3 expression in macrophages and cancer cells by relieving CREB-mediated repression of the CCL3 promoter via ROS accumulation. DTX-induced CCL3 then promotes proinflammatory macrophage polarization via the CCL3-CCR5-p38/IRF5 signaling pathway, which subsequently facilitates macrophage phagocytosis of breast cancer cells.","method":"Ccl3-KO mice, macrophage depletion, RNA sequencing, CREB inhibitor, ROS measurement, CCR5 and p38/IRF5 pathway analysis, phagocytosis assay","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and pharmacological approaches defining the mechanism; single lab","pmids":["35613826"],"is_preprint":false},{"year":2024,"finding":"H. pylori infection stimulates macrophages to secrete CCL3 via the JAK1-STAT1 pathway (with STAT1 identified as a direct transcription factor for the CCL3 promoter by ChIP assay). CCL3 then damages gastric epithelial tight junctions by activating P38 phosphorylation; neutralizing anti-CCL3 antibody or CCL3 receptor inhibitor restored tight junction integrity.","method":"RT-qPCR, Western blot, ELISA, dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP), transepithelial electrical resistance, immunofluorescence, in vivo mouse CCL3 injection","journal":"Cell communication and signaling","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP identifying direct TF binding + functional pathway (JAK1-STAT1→CCL3→P38→tight junction disruption) with rescue experiments; single lab","pmids":["38730482"],"is_preprint":false},{"year":2024,"finding":"In cartilage endplate chondrocytes under abnormal mechanical stress, Hippo signaling activation suppresses YAP1, which in turn de-represses the CCL3 promoter, leading to CCL3 release that recruits osteoclasts and promotes endplate remodeling. YAP1 overexpression (via AAV5) inhibited CCL3 transcription by blocking its promoter, reversing endplate remodeling and disc degeneration.","method":"Transcriptome sequencing, Yap1 conditional knockout and overexpression (AAV5), lumbar spine instability mouse model, in vitro stress experiments","journal":"Bone research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic manipulation (KO + OE) with direct promoter blocking and in vivo rescue; single lab","pmids":["38816384"],"is_preprint":false},{"year":2023,"finding":"CCL3 in the aging bone marrow microenvironment promotes adipogenic differentiation of BMSCs via activation of STAT3 → C/EBPα, with a positive feedback loop where C/EBPα directly binds the CCL3 promoter (facilitated by DNA hypomethylation) to further activate CCL3 expression. CCL3 also inhibits osteogenic differentiation by blocking β-catenin activity through ERK-activated DKK1 upregulation. In vivo CCL3 deletion or neutralization rescued bone loss and marrow adiposity in aged mice.","method":"Antibody array, Ccl3-/- mice, in vivo neutralizing antibody treatment, BMSC differentiation assays, ChIP, Western blot for STAT3/C/EBPα/β-catenin/DKK1/ERK","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion + neutralization rescue + mechanistic dissection with ChIP and multiple signaling nodes; single lab but multiple orthogonal approaches","pmids":["36378535"],"is_preprint":false},{"year":2012,"finding":"CCL3 and its receptor CCR5 are required for maintenance (but not initiation) of chronic pelvic pain in experimental autoimmune prostatitis (EAP). CCL3-/- mice showed resistance to maintenance of pelvic pain while CCR5-/- mice did not, indicating CCL3 acts through a CCR5-independent mechanism for pain maintenance.","method":"CCL3-/-, CCR5-/-, CCR2-/- mice, neutralizing antibodies, bone marrow reconstitution, von Frey and thermal pain assays","journal":"American journal of physiology - regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple KO mice with pain behavioral endpoints; single lab","pmids":["22814670"],"is_preprint":false}],"current_model":"CCL3 (MIP-1α/LD78α) is a CC chemokine that signals through G protein-coupled receptors CCR1 and CCR5 to exert chemotaxis of monocytes, T cells, neutrophils, and NK cells; it forms polydisperse rod-shaped double-helical polymers (polymerization buries receptor-binding sites and protects the chemokine from proteolytic degradation by IDE, which selectively cleaves monomers); its mRNA is post-transcriptionally regulated by the ARE-binding protein tristetraprolin; it is transcriptionally controlled downstream of FGFR3/RAS-MAPK and Hippo/YAP1 signaling, with STAT1 as a direct promoter-binding transcription factor; neutrophil-derived serine proteases (cathepsin G, elastase, proteinase 3) cleave and inactivate it at defined sites; and functionally it suppresses hematopoietic stem cell and keratinocyte proliferation, promotes osteoclastogenesis, drives viral-induced inflammation, mediates HIV suppression via competitive CCR5 occupancy (with the LD78β isoform showing far greater potency due to a Pro-2 residue), and activates downstream PI3K/AKT and MAPK/ERK cell survival/migration cascades in multiple cell types."},"narrative":{"mechanistic_narrative":"CCL3 (MIP-1α/LD78α) is a secreted CC chemokine that orchestrates leukocyte recruitment and inflammatory responses by signaling through the G protein-coupled receptors CCR1 and CCR5 [PMID:7505609, PMID:18941229, PMID:20870892]. It was identified as a major CD8+ T cell-derived HIV-suppressive factor, blocking HIV-1, HIV-2, and SIV replication, and its non-allelic isoform LD78β shows markedly greater receptor affinity and HIV-suppressive potency owing to a proline at position 2 [PMID:8525373, PMID:10364178]. In vivo, CCL3 is required for normal inflammatory responses to viral infection and drives a broad spectrum of pathologies through receptor-restricted signaling: CCR1-dependent recruitment of leukocytes underlies radiation-induced lung fibrosis, T cell-mediated hepatitis, hepatocellular carcinoma progression, and NK-cell mobilization from bone marrow, whereas CCR5-dependent signaling promotes lung metastasis and macrophage/fibroblast accumulation [PMID:7667639, PMID:18941229, PMID:16284949, PMID:20870892, PMID:15368307, PMID:18227348]. Downstream of its receptors CCL3 activates PI3K/AKT and MAPK/ERK survival and migration cascades, as well as p38, JNK, NF-κB, and AMPK branches that drive MMP and VEGF-A expression in tumor cells and tight-junction disruption in gastric epithelium [PMID:12506012, PMID:26713602, PMID:24047437, PMID:38730482]. CCL3 exerts cell-type-specific effects on proliferation and differentiation, suppressing hematopoietic progenitor and keratinocyte proliferation while promoting myeloid differentiation, osteoclastogenesis, and—in the aging marrow—adipogenic over osteogenic BMSC differentiation [PMID:1571537, PMID:8345211, PMID:9121122, PMID:30279500, PMID:36378535]. Structurally, CCL3 self-associates into rod-shaped double-helical oligomers stabilized by glycosaminoglycan binding; polymerization buries receptor-binding sites and protects against degradation, while insulin-degrading enzyme selectively cleaves monomers and neutrophil serine proteases (cathepsin G, elastase, proteinase 3) inactivate it at defined sites [PMID:20959807, PMID:27091995, PMID:15728180, PMID:8499450]. Its expression is tightly controlled transcriptionally—downstream of FGFR3/RAS-MAPK and Hippo/YAP1 signaling, with STAT1 binding the promoter directly—and post-transcriptionally through tristetraprolin-mediated destabilization of its AU-rich mRNA [PMID:21784977, PMID:16849642, PMID:38730482, PMID:38816384].","teleology":[{"year":1992,"claim":"Established the first non-chemotactic functional role of CCL3 as a negative regulator of progenitor cell proliferation, defining it as more than an inflammatory mediator.","evidence":"In vitro CFU-S colony assays and in vivo myeloprotection after chemotherapy; in vitro clonogenic keratinocyte assays with mRNA localization to Langerhans cells","pmids":["1571537","8345211"],"confidence":"High","gaps":["Receptor and signaling mechanism of growth inhibition not defined","Whether inhibition is direct or paracrine-mediated unresolved"]},{"year":1993,"claim":"Identified CCR1 as a functional GPCR for CCL3 and began characterizing its self-association behavior and promoter regulation, anchoring receptor signaling and gene control.","evidence":"Stable transfectants with cAMP/calcium readouts; analytical ultracentrifugation/CD/fluorescence on oligomeric states; promoter deletion, EMSA, and footprinting","pmids":["7505609","8499450","8474441"],"confidence":"High","gaps":["Structural basis of oligomerization not yet resolved","Functional consequence of multimeric vs monomeric forms unknown at this stage","Identity of ICK-1 binding factors not molecularly defined"]},{"year":1995,"claim":"Defined CCL3 as a major HIV-suppressive factor and demonstrated its non-redundant requirement for antiviral inflammatory responses in vivo.","evidence":"Protein purification, neutralizing antibody blockade, recombinant inhibition of HIV/SIV; MIP-1α knockout mice in Coxsackievirus and influenza models","pmids":["8525373","7667639"],"confidence":"High","gaps":["Receptor competition mechanism of HIV suppression not yet defined","Cell types mediating in vivo antiviral effect not fully resolved"]},{"year":1999,"claim":"Resolved why CCL3 isoforms differ functionally by pinpointing a single Pro-2 residue in LD78β that drives enhanced CCR5/D6 binding and HIV suppression.","evidence":"Receptor binding affinity assays, Pro-2 site-directed mutagenesis, HIV-1 suppression assays","pmids":["10364178"],"confidence":"High","gaps":["Structural basis of Pro-2-conferred affinity not determined","Physiological relevance of isoform ratio in vivo unaddressed"]},{"year":2004,"claim":"Demonstrated receptor-specific roles for CCL3 in tissue pathology and dissected a novel transcriptional repression pathway, separating CCR1- and CCR5-driven effects.","evidence":"CCR1-/- and CCL3-/- mice in HCC and Con A hepatitis models with met-RANTES blockade; PGE2 pathway dissection (EP2→cAMP→EPAC→PI3K→PKB→GSK3→CDP) with siRNA","pmids":["16284949","15368307","15498767"],"confidence":"High","gaps":["Whether CCR1 effects are direct on tumor cells or via recruited leukocytes not fully resolved","Generality of CDP repression across cell types unknown"]},{"year":2008,"claim":"Established CCL3-CCR5 as a driver of the metastatic tumor microenvironment and CCL3-CCR1 as a regulator of NK cell trafficking, broadening its physiological reach.","evidence":"CCL3-/- and CCR5-/- mice with bone marrow chimeras and MMP-9/HGF induction assays; NK cell subset chemotaxis and in vivo mobilization with AMD-3100","pmids":["18941229","18227348"],"confidence":"High","gaps":["Mechanism of CXCL12 priming of NK responsiveness not molecularly defined","Relative contributions of stromal vs hematopoietic CCL3 sources incompletely mapped"]},{"year":2010,"claim":"Solved the structural and biophysical logic of CCL3 self-assembly, showing polymerization regulates receptor accessibility and proteolytic stability.","evidence":"X-ray crystallography, SEC/AUC, mutagenesis, monocyte arrest assays, IDE knockdown; endothelial polarized presentation by immunoelectron microscopy","pmids":["20959807","20047691"],"confidence":"High","gaps":["In vivo significance of polymer vs monomer equilibrium not quantified","How polymer disassembly is regulated physiologically unknown"]},{"year":2011,"claim":"Defined post-transcriptional control of CCL3 by tristetraprolin and proved its causal role in inflammatory disease via genetic epistasis.","evidence":"TTP-bound mRNA screen and RIP in macrophages; CCL3-/-/TTP-/- double-KO rescue of arthritis and atherosclerosis","pmids":["21784977"],"confidence":"High","gaps":["Other ARE-binding proteins acting on CCL3 mRNA not surveyed","Tissue specificity of TTP-mediated control not detailed"]},{"year":2016,"claim":"Refined the structural understanding of CCL3 oligomers in complex with glycosaminoglycans, revealing a distinct GAG-binding groove and conformational plasticity of the N-terminus.","evidence":"X-ray crystallography of GAG-bound oligomers, biophysical analyses, mutagenesis","pmids":["27091995"],"confidence":"High","gaps":["In vivo role of GAG-anchored oligomers in haptotactic gradients not directly tested","Link between N-terminal conformation and receptor signaling not established"]},{"year":2018,"claim":"Clarified the hematopoietic function of CCL3 by showing it promotes myeloid lineage differentiation and constrains the HSPC pool independently of the bone marrow niche.","evidence":"CCL3-/- mice with flow cytometry of hematopoietic compartments and microenvironment analysis","pmids":["30279500"],"confidence":"Medium","gaps":["Cell-intrinsic vs extrinsic mechanism of differentiation promotion unresolved","Receptor mediating this effect not identified"]},{"year":2024,"claim":"Identified direct transcriptional control of CCL3 by STAT1 and by Hippo/YAP1, completing a picture of multilayered upstream regulation linked to epithelial and skeletal pathology.","evidence":"ChIP of STAT1 at the CCL3 promoter with JAK1-STAT1→CCL3→p38 tight-junction disruption rescue; Yap1 conditional KO/AAV5 overexpression with promoter blocking in disc degeneration model","pmids":["38730482","38816384"],"confidence":"High","gaps":["Interplay between STAT1, YAP1, FGFR3/RAS, and CDP at the promoter not integrated","Context determining which upstream input dominates not defined"]},{"year":null,"claim":"How the structural state of CCL3 (monomer, oligomer, GAG-bound polymer) is dynamically tuned in vivo to bias CCR1 versus CCR5 engagement and select among its many context-specific outcomes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No in vivo measurement linking oligomeric state to receptor choice","Determinants of CCR1 vs CCR5 selectivity in a given tissue undefined","Unified model integrating proteolysis, polymerization, and transcriptional control absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,5,11,15]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,10,27]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,11,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,10,27,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,14,15,24,25]}],"complexes":[],"partners":["CCR1","CCR5","ZFP36","IDE"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P10147","full_name":"C-C motif chemokine 3","aliases":["G0/G1 switch regulatory protein 19-1","Macrophage inflammatory protein 1-alpha","MIP-1-alpha","PAT 464.1","SIS-beta","Small-inducible cytokine A3","Tonsillar lymphocyte LD78 alpha protein"],"length_aa":92,"mass_kda":10.1,"function":"Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P10147/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL3","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1165,"dependency_fraction":0.0017167381974248926},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL3","total_profiled":1310},"omim":[{"mim_id":"614061","title":"OLFACTOMEDIN 4; OLFM4","url":"https://www.omim.org/entry/614061"},{"mim_id":"613665","title":"ATYPICAL CHEMOKINE RECEPTOR 1; ACKR1","url":"https://www.omim.org/entry/613665"},{"mim_id":"610369","title":"HEAT-SHOCK 70-KD PROTEIN 14; HSPA14","url":"https://www.omim.org/entry/610369"},{"mim_id":"609467","title":"CHEMOKINE, CC MOTIF, LIGAND 3, PSEUDOGENE 1; CCL3P1","url":"https://www.omim.org/entry/609467"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":72.7},{"tissue":"lung","ntpm":35.3},{"tissue":"lymphoid tissue","ntpm":48.7}],"url":"https://www.proteinatlas.org/search/CCL3"},"hgnc":{"alias_symbol":["G0S19-1","LD78ALPHA","MIP-1-alpha","LD78","SCI"],"prev_symbol":["SCYA3"]},"alphafold":{"accession":"P10147","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10147","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10147-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10147-F1-predicted_aligned_error_v6.png","plddt_mean":88.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL3","jax_strain_url":"https://www.jax.org/strain/search?query=CCL3"},"sequence":{"accession":"P10147","fasta_url":"https://rest.uniprot.org/uniprotkb/P10147.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10147/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10147"}},"corpus_meta":[{"pmid":"8525373","id":"PMC_8525373","title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8525373","citation_count":2552,"is_preprint":false},{"pmid":"7667639","id":"PMC_7667639","title":"Requirement of MIP-1 alpha for an inflammatory response to viral infection.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7667639","citation_count":515,"is_preprint":false},{"pmid":"25762141","id":"PMC_25762141","title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/25762141","citation_count":439,"is_preprint":false},{"pmid":"9233607","id":"PMC_9233607","title":"A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9233607","citation_count":200,"is_preprint":false},{"pmid":"12506012","id":"PMC_12506012","title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12506012","citation_count":184,"is_preprint":false},{"pmid":"1571537","id":"PMC_1571537","title":"Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo.","date":"1992","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1571537","citation_count":177,"is_preprint":false},{"pmid":"8558069","id":"PMC_8558069","title":"The role of MIP-1 alpha in inflammation and hematopoiesis.","date":"1996","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/8558069","citation_count":172,"is_preprint":false},{"pmid":"9372648","id":"PMC_9372648","title":"Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge.","date":"1997","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9372648","citation_count":165,"is_preprint":false},{"pmid":"7722328","id":"PMC_7722328","title":"Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7722328","citation_count":144,"is_preprint":false},{"pmid":"7505609","id":"PMC_7505609","title":"Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors.","date":"1993","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7505609","citation_count":142,"is_preprint":false},{"pmid":"9570566","id":"PMC_9570566","title":"Cytokine induction of MIP-1 alpha and MIP-1 beta in human fetal microglia.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9570566","citation_count":140,"is_preprint":false},{"pmid":"20047691","id":"PMC_20047691","title":"Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide.","date":"2010","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/20047691","citation_count":138,"is_preprint":false},{"pmid":"20959807","id":"PMC_20959807","title":"Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20959807","citation_count":138,"is_preprint":false},{"pmid":"18941229","id":"PMC_18941229","title":"CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18941229","citation_count":138,"is_preprint":false},{"pmid":"28965431","id":"PMC_28965431","title":"Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.","date":"2017","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28965431","citation_count":124,"is_preprint":false},{"pmid":"1694014","id":"PMC_1694014","title":"Structures of human genes coding for cytokine LD78 and their expression.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1694014","citation_count":117,"is_preprint":false},{"pmid":"21115978","id":"PMC_21115978","title":"CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21115978","citation_count":111,"is_preprint":false},{"pmid":"10364178","id":"PMC_10364178","title":"LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10364178","citation_count":110,"is_preprint":false},{"pmid":"18227348","id":"PMC_18227348","title":"CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18227348","citation_count":96,"is_preprint":false},{"pmid":"17618978","id":"PMC_17618978","title":"Sodium channel expression and the molecular pathophysiology of pain after SCI.","date":"2007","source":"Progress in brain research","url":"https://pubmed.ncbi.nlm.nih.gov/17618978","citation_count":86,"is_preprint":false},{"pmid":"26713602","id":"PMC_26713602","title":"CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26713602","citation_count":85,"is_preprint":false},{"pmid":"32060842","id":"PMC_32060842","title":"CCL3 Signaling in the Tumor Microenvironment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060842","citation_count":83,"is_preprint":false},{"pmid":"25017887","id":"PMC_25017887","title":"Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense.","date":"2014","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25017887","citation_count":83,"is_preprint":false},{"pmid":"16284949","id":"PMC_16284949","title":"Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progression.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16284949","citation_count":83,"is_preprint":false},{"pmid":"17621255","id":"PMC_17621255","title":"TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome.","date":"2008","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/17621255","citation_count":78,"is_preprint":false},{"pmid":"9121122","id":"PMC_9121122","title":"Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment.","date":"1997","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9121122","citation_count":77,"is_preprint":false},{"pmid":"32457351","id":"PMC_32457351","title":"CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways.","date":"2020","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32457351","citation_count":71,"is_preprint":false},{"pmid":"15498767","id":"PMC_15498767","title":"A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15498767","citation_count":70,"is_preprint":false},{"pmid":"21360237","id":"PMC_21360237","title":"Targeting microvasculature for neuroprotection after SCI.","date":"2011","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21360237","citation_count":67,"is_preprint":false},{"pmid":"33246483","id":"PMC_33246483","title":"CCL3 contributes to secondary damage after spinal cord injury.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33246483","citation_count":67,"is_preprint":false},{"pmid":"23288165","id":"PMC_23288165","title":"Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation.","date":"2013","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23288165","citation_count":67,"is_preprint":false},{"pmid":"27091995","id":"PMC_27091995","title":"Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27091995","citation_count":66,"is_preprint":false},{"pmid":"15368307","id":"PMC_15368307","title":"CCL3/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15368307","citation_count":66,"is_preprint":false},{"pmid":"22814670","id":"PMC_22814670","title":"CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis.","date":"2012","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22814670","citation_count":66,"is_preprint":false},{"pmid":"35613826","id":"PMC_35613826","title":"Ccl3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35613826","citation_count":65,"is_preprint":false},{"pmid":"27308309","id":"PMC_27308309","title":"Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308309","citation_count":63,"is_preprint":false},{"pmid":"16849642","id":"PMC_16849642","title":"MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16849642","citation_count":59,"is_preprint":false},{"pmid":"32006659","id":"PMC_32006659","title":"CCL3/CCR1 mediates CD14+CD16- circulating monocyte recruitment in knee osteoarthritis progression.","date":"2020","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/32006659","citation_count":56,"is_preprint":false},{"pmid":"2033269","id":"PMC_2033269","title":"Genomic structure of murine macrophage inflammatory protein-1 alpha and conservation of potential regulatory sequences with a human homolog, LD78.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2033269","citation_count":55,"is_preprint":false},{"pmid":"25183374","id":"PMC_25183374","title":"Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum.","date":"2014","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/25183374","citation_count":55,"is_preprint":false},{"pmid":"20870892","id":"PMC_20870892","title":"The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis.","date":"2010","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20870892","citation_count":54,"is_preprint":false},{"pmid":"21784977","id":"PMC_21784977","title":"Zinc finger protein tristetraprolin interacts with CCL3 mRNA and regulates tissue inflammation.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21784977","citation_count":54,"is_preprint":false},{"pmid":"15829914","id":"PMC_15829914","title":"Superoxide dismutase 1 overexpression reduces MCP-1 and MIP-1 alpha expression after transient focal cerebral ischemia.","date":"2005","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15829914","citation_count":52,"is_preprint":false},{"pmid":"2687328","id":"PMC_2687328","title":"Synthesis of a novel cytokine and its gene (LD78) expressions in hematopoietic fresh tumor cells and cell lines.","date":"1989","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2687328","citation_count":51,"is_preprint":false},{"pmid":"27522478","id":"PMC_27522478","title":"Role of interleukin-4, the chemokine CCL3 and its receptor CCR5 in neuropathic pain.","date":"2016","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27522478","citation_count":50,"is_preprint":false},{"pmid":"15728180","id":"PMC_15728180","title":"Proteolysis of macrophage inflammatory protein-1alpha isoforms LD78beta and LD78alpha by neutrophil-derived serine proteases.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15728180","citation_count":49,"is_preprint":false},{"pmid":"15634233","id":"PMC_15634233","title":"Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies.","date":"2005","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15634233","citation_count":45,"is_preprint":false},{"pmid":"1617159","id":"PMC_1617159","title":"Biological and structural properties of MIP-1 alpha expressed in yeast.","date":"1992","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/1617159","citation_count":45,"is_preprint":false},{"pmid":"28881626","id":"PMC_28881626","title":"Relevance of CCL3/CCR5 axis in oral carcinogenesis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881626","citation_count":41,"is_preprint":false},{"pmid":"8345211","id":"PMC_8345211","title":"Hemopoietic stem cell inhibitor (SCI/MIP-1 alpha) also inhibits clonogenic epidermal keratinocyte proliferation.","date":"1993","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8345211","citation_count":41,"is_preprint":false},{"pmid":"9021919","id":"PMC_9021919","title":"MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans.","date":"1997","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9021919","citation_count":40,"is_preprint":false},{"pmid":"30279500","id":"PMC_30279500","title":"The Chemokine CCL3 Regulates Myeloid Differentiation and Hematopoietic Stem Cell Numbers.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30279500","citation_count":39,"is_preprint":false},{"pmid":"20524925","id":"PMC_20524925","title":"Cardiovascular disease, SCI and exercise: unique risks and focused countermeasures.","date":"2010","source":"Disability and rehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/20524925","citation_count":38,"is_preprint":false},{"pmid":"11536240","id":"PMC_11536240","title":"MIP-1 alpha and MIP-1 beta induction by dengue virus.","date":"2001","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/11536240","citation_count":38,"is_preprint":false},{"pmid":"38816384","id":"PMC_38816384","title":"Lumbar instability remodels cartilage endplate to induce intervertebral disc degeneration by recruiting osteoclasts via Hippo-CCL3 signaling.","date":"2024","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/38816384","citation_count":37,"is_preprint":false},{"pmid":"24047437","id":"PMC_24047437","title":"AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma.","date":"2013","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/24047437","citation_count":37,"is_preprint":false},{"pmid":"9702779","id":"PMC_9702779","title":"Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library.","date":"1998","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/9702779","citation_count":36,"is_preprint":false},{"pmid":"10049593","id":"PMC_10049593","title":"Chemokine PARC gene (SCYA18) generated by fusion of two MIP-1alpha/LD78alpha-like genes.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10049593","citation_count":35,"is_preprint":false},{"pmid":"31508417","id":"PMC_31508417","title":"Long Non-coding RNA HOTTIP Promotes CCL3 Expression and Induces Cartilage Degradation by Sponging miR-455-3p.","date":"2019","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31508417","citation_count":35,"is_preprint":false},{"pmid":"8474441","id":"PMC_8474441","title":"Characterization of cytokine LD78 gene promoters: positive and negative transcriptional factors bind to a negative regulatory element common to LD78, interleukin-3, and granulocyte-macrophage colony-stimulating factor gene promoters.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8474441","citation_count":34,"is_preprint":false},{"pmid":"27109512","id":"PMC_27109512","title":"Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1α/CCL3.","date":"2016","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/27109512","citation_count":34,"is_preprint":false},{"pmid":"31494219","id":"PMC_31494219","title":"The effects of CCL3, CCL4, CCL19 and CCL21 as molecular adjuvants on the immune response to VAA DNA vaccine in flounder (Paralichthys olivaceus).","date":"2019","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31494219","citation_count":33,"is_preprint":false},{"pmid":"1601173","id":"PMC_1601173","title":"SCI/MIP-1 alpha: a potent stem cell inhibitor with potential roles in development.","date":"1992","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/1601173","citation_count":31,"is_preprint":false},{"pmid":"21349590","id":"PMC_21349590","title":"Equine herpesvirus type-1 modulates CCL2, CCL3, CCL5, CXCL9, and CXCL10 chemokine expression.","date":"2011","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/21349590","citation_count":29,"is_preprint":false},{"pmid":"26663750","id":"PMC_26663750","title":"Involvement of CC Chemokine Receptor 1 and CCL3 in Acute and Chronic Inflammatory Pain in Mice.","date":"2016","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26663750","citation_count":29,"is_preprint":false},{"pmid":"31898342","id":"PMC_31898342","title":"Transcription factor RUNX3 promotes CD8+ T cell recruitment by CCL3 and CCL20 in lung adenocarcinoma immune microenvironment.","date":"2020","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31898342","citation_count":29,"is_preprint":false},{"pmid":"15043189","id":"PMC_15043189","title":"MIP-1 alpha and myeloma bone disease.","date":"2004","source":"Cancer treatment and research","url":"https://pubmed.ncbi.nlm.nih.gov/15043189","citation_count":28,"is_preprint":false},{"pmid":"25060177","id":"PMC_25060177","title":"Serum CCL2 and CCL3 as potential biomarkers for the diagnosis of oral squamous cell carcinoma.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25060177","citation_count":28,"is_preprint":false},{"pmid":"23760235","id":"PMC_23760235","title":"Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/23760235","citation_count":28,"is_preprint":false},{"pmid":"30755656","id":"PMC_30755656","title":"Dendritic cell targeted Ccl3- and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30755656","citation_count":27,"is_preprint":false},{"pmid":"1468544","id":"PMC_1468544","title":"Expression of stem cell inhibitor (SCI) gene in patients with bone marrow failure.","date":"1992","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/1468544","citation_count":27,"is_preprint":false},{"pmid":"37227653","id":"PMC_37227653","title":"The Role of CCL3 in the Pathogenesis of Rheumatoid Arthritis.","date":"2023","source":"Rheumatology and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37227653","citation_count":26,"is_preprint":false},{"pmid":"31493490","id":"PMC_31493490","title":"Mechanisms of Below-Level Pain Following Spinal Cord Injury (SCI).","date":"2019","source":"The journal of pain","url":"https://pubmed.ncbi.nlm.nih.gov/31493490","citation_count":26,"is_preprint":false},{"pmid":"33535036","id":"PMC_33535036","title":"Systematic analysis of purified astrocytes after SCI unveils Zeb2os function during astrogliosis.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33535036","citation_count":26,"is_preprint":false},{"pmid":"35403834","id":"PMC_35403834","title":"A Selective β-Catenin-Metadherin/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35403834","citation_count":25,"is_preprint":false},{"pmid":"38730482","id":"PMC_38730482","title":"Helicobacter pylori disrupts gastric mucosal homeostasis by stimulating macrophages to secrete CCL3.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/38730482","citation_count":23,"is_preprint":false},{"pmid":"27830143","id":"PMC_27830143","title":"MicroRNA-146a Contributes to SCI Recovery via Regulating TRAF6 and IRAK1 Expression.","date":"2016","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/27830143","citation_count":23,"is_preprint":false},{"pmid":"28094821","id":"PMC_28094821","title":"Upregulation of CCL3/MIP-1alpha regulated by MAPKs and NF-kappaB mediates microglial inflammatory response in LPS-induced brain injury.","date":"2016","source":"Acta neurobiologiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/28094821","citation_count":23,"is_preprint":false},{"pmid":"36691046","id":"PMC_36691046","title":"CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m6A) modification.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36691046","citation_count":23,"is_preprint":false},{"pmid":"20452453","id":"PMC_20452453","title":"Role of CCL3/MIP-1alpha and CCL5/RANTES during acute Trypanosoma cruzi infection in rats.","date":"2010","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/20452453","citation_count":23,"is_preprint":false},{"pmid":"24809505","id":"PMC_24809505","title":"Chemokine expression of CCL2, CCL3, CCL5 and CXCL10 during early inflammatory tendon healing precedes nerve regeneration: an immunohistochemical study in the rat.","date":"2014","source":"Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA","url":"https://pubmed.ncbi.nlm.nih.gov/24809505","citation_count":23,"is_preprint":false},{"pmid":"31316152","id":"PMC_31316152","title":"RNA sequencing analysis revealed the induction of CCL3 expression in human intracranial aneurysms.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31316152","citation_count":22,"is_preprint":false},{"pmid":"31793629","id":"PMC_31793629","title":"Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice.","date":"2020","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31793629","citation_count":22,"is_preprint":false},{"pmid":"8187954","id":"PMC_8187954","title":"MIP-1 alpha is a regulator of mitotic and meiotic DNA synthesis during spermatogenesis.","date":"1994","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8187954","citation_count":22,"is_preprint":false},{"pmid":"7537510","id":"PMC_7537510","title":"Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4.","date":"1995","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/7537510","citation_count":21,"is_preprint":false},{"pmid":"10471782","id":"PMC_10471782","title":"Enhanced anti-HIV-1 activity of CC-chemokine LD78beta, a non-allelic variant of MIP-1alpha/LD78alpha.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10471782","citation_count":21,"is_preprint":false},{"pmid":"33981848","id":"PMC_33981848","title":"Recombinant Bacteroides fragilis enterotoxin-1 (rBFT-1) promotes proliferation of colorectal cancer via CCL3-related molecular pathways.","date":"2021","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33981848","citation_count":21,"is_preprint":false},{"pmid":"34732692","id":"PMC_34732692","title":"PIWI-interacting RNA 57125 restrains clear cell renal cell carcinoma metastasis by downregulating CCL3 expression.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34732692","citation_count":21,"is_preprint":false},{"pmid":"8298472","id":"PMC_8298472","title":"Contrasting effects of rh-MIP-1 alpha and TGF-beta 1 on chronic myeloid leukemia progenitors in vitro.","date":"1993","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/8298472","citation_count":21,"is_preprint":false},{"pmid":"36346222","id":"PMC_36346222","title":"CCL3-CCR5 axis promotes cell migration and invasion of colon adenocarcinoma via Akt signaling pathway.","date":"2022","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36346222","citation_count":20,"is_preprint":false},{"pmid":"1296815","id":"PMC_1296815","title":"Nucleotide sequence of the third cytokine LD78 gene and mapping of all three LD78 gene loci to human chromosome 17.","date":"1992","source":"DNA sequence : the journal of DNA sequencing and mapping","url":"https://pubmed.ncbi.nlm.nih.gov/1296815","citation_count":20,"is_preprint":false},{"pmid":"8499450","id":"PMC_8499450","title":"Characterization of the quaternary structure and conformational properties of the human stem cell inhibitor protein LD78 in solution.","date":"1993","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8499450","citation_count":20,"is_preprint":false},{"pmid":"8453306","id":"PMC_8453306","title":"T-cell chemotactic activity of cytokine LD78: a comparative study with interleukin-8, a chemotactic factor for the T-cell CD45RA+ phenotype.","date":"1993","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8453306","citation_count":20,"is_preprint":false},{"pmid":"9175116","id":"PMC_9175116","title":"Expression and distribution of CC chemokine macrophage inflammatory protein-1 alpha/LD78 in the human brain.","date":"1997","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/9175116","citation_count":19,"is_preprint":false},{"pmid":"36385234","id":"PMC_36385234","title":"Moderate-Intensity Treadmill Exercise Promotes mTOR-Dependent Motor Cortical Neurotrophic Factor Expression and Functional Recovery in a Murine Model of Crush Spinal Cord Injury (SCI).","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36385234","citation_count":19,"is_preprint":false},{"pmid":"38335607","id":"PMC_38335607","title":"The interplay of Cxcl10+/Mmp14+ monocytes and Ccl3+ neutrophils proactively mediates silica-induced pulmonary fibrosis.","date":"2024","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/38335607","citation_count":18,"is_preprint":false},{"pmid":"9849450","id":"PMC_9849450","title":"Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.","date":"1998","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/9849450","citation_count":18,"is_preprint":false},{"pmid":"36550354","id":"PMC_36550354","title":"CCL3 aggravates intestinal damage in NEC by promoting macrophage chemotaxis and M1 macrophage polarization.","date":"2022","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/36550354","citation_count":18,"is_preprint":false},{"pmid":"36378535","id":"PMC_36378535","title":"CCL3 in the bone marrow microenvironment causes bone loss and bone marrow adiposity in aged mice.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36378535","citation_count":18,"is_preprint":false},{"pmid":"19285486","id":"PMC_19285486","title":"CCL3/MIP-1 alpha is not involved in the LPS-induced fever and its pyrogenic activity depends on CRF.","date":"2009","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19285486","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50937,"output_tokens":8682,"usd":0.14152,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18810,"output_tokens":4167,"usd":0.099113,"stage2_stop_reason":"end_turn"},"total_usd":0.240633,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL3 (MIP-1α), along with RANTES and MIP-1β, was identified as a major HIV-suppressive factor produced by CD8+ T cells. Purified proteins from CD8+ T cell supernatants showed sequence identity with RANTES and MIP-1α; neutralizing antibody combinations against all three chemokines completely blocked HIV-SF activity; recombinant CCL3 caused dose-dependent inhibition of HIV-1, HIV-2, and SIV replication.\",\n      \"method\": \"Protein purification from cell supernatants, sequence identity, neutralizing antibody blockade, recombinant protein inhibition assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (purification, sequencing, neutralizing antibody combination blockade, recombinant protein assay); widely replicated and highly cited\",\n      \"pmids\": [\"8525373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MIP-1α (CCL3) is required in vivo for a normal inflammatory response to viral infection. CCL3-knockout mice were resistant to Coxsackievirus-induced myocarditis and showed reduced pneumonitis and delayed clearance of influenza virus, with no overt hematopoietic abnormalities.\",\n      \"method\": \"Gene knockout mouse model (MIP-1α -/- mice), viral infection models (Coxsackievirus, influenza), histological and virological assessment\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined phenotypic readout across two viral models, replicated finding\",\n      \"pmids\": [\"7667639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"HM145 (later identified as CCR1) is a functional G protein-coupled receptor for LD78 (CCL3), as demonstrated by decreased cAMP accumulation and calcium influx in stable transfectants expressing HM145 upon LD78 stimulation.\",\n      \"method\": \"Stable transfection, cAMP accumulation assay, calcium influx measurement\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — functional receptor identification via two orthogonal second-messenger readouts in stable transfectants\",\n      \"pmids\": [\"7505609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL3 (MIP-1α) and CCL4 (MIP-1β) form rod-shaped, double-helical polymers via a polymerization process. Polymerization buries receptor-binding sites of CCL3, so depolymerization mutations enhance CCL3's ability to arrest monocytes on activated endothelium. Insulin-degrading enzyme (IDE) selectively degrades monomeric CCL3, and decreased IDE expression leads to elevated CCL3 in microglial cells.\",\n      \"method\": \"X-ray crystallography, biophysical analysis (SEC, AUC), mathematical modelling, mutagenesis, monocyte arrest assay, proteomics, IDE knockdown in microglial cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mutagenesis and multiple orthogonal biophysical/functional validations in one study\",\n      \"pmids\": [\"20959807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of CCL3 oligomers bound to glycosaminoglycans (GAGs) revealed that CCL3 forms rod-shaped double-helical oligomers and uses a distinct GAG-binding groove formed by residues from two partially buried BBXB motifs. An alternative CCL3 oligomer structure showed that conformational changes in the N-termini profoundly alter surface properties and dimer-dimer interactions, affecting both GAG binding and oligomerization.\",\n      \"method\": \"X-ray crystallography, biophysical analyses, mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of GAG-bound CCL3 oligomers with structural and mutagenic validation\",\n      \"pmids\": [\"27091995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"LD78β (MIP-1αP), a non-allelic isoform of CCL3 (LD78α), has ~6-fold enhanced binding affinity to CCR5 and ~15–20-fold enhanced affinity to the D6 receptor compared to LD78α. A proline residue at position 2 of LD78β is responsible for this enhanced receptor binding activity and markedly higher HIV-1 suppressive activity.\",\n      \"method\": \"Receptor binding affinity assays, site-directed mutagenesis (Pro-2 substitution), HIV-1 suppression assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis identifying specific residue + receptor binding + functional HIV suppression assays\",\n      \"pmids\": [\"10364178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Neutrophil-derived serine proteases (cathepsin G, elastase, proteinase 3) cleave CCL3 isoforms LD78β and LD78α at specific sites (Thr16-Ser17, Phe24-Ile25, Tyr28-Phe29, Thr31-Ser32), with cathepsin G preferentially cleaving at Phe24-Ile25 and Tyr28-Phe29 and elastase/proteinase 3 at Thr16-Ser17 and Thr31-Ser32. Proteolysis of LD78β results in loss of chemotactic activity.\",\n      \"method\": \"In vitro protease cleavage assay, mass spectrometry and peptide sequencing, serine protease inhibitor studies, neutrophil lysates from Papillon-Lefèvre syndrome patients, chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro cleavage with MS/sequencing to define sites, mutant patient cell validation, functional loss demonstrated\",\n      \"pmids\": [\"15728180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The LD78α gene promoter contains multiple positive and negative regulatory elements. A negative regulatory element (ICK-1) is a binding site for both positive (ICK-1B) and negative (ICK-1A) transcriptional factors; an ICK-1-like element is shared with IL-3 and GM-CSF gene promoters, suggesting common transcriptional control among hematopoietic growth factors.\",\n      \"method\": \"Promoter deletion analysis, electrophoretic mobility shift assay (EMSA), in vivo footprinting, transfection/reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and reporter assays defining specific regulatory elements; single-lab study\",\n      \"pmids\": [\"8474441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PGE2 inhibits CCL3 and CCL4 expression in dendritic cells via a novel signaling pathway: EP-2 → cAMP → EPAC → PI3-kinase → PKB → GSK-3, leading to increased DNA binding of the CCAAT displacement protein (CDP), a transcriptional repressor; CDP knockdown with siRNA directly linked CDP to CCL3/4 transcription.\",\n      \"method\": \"Pharmacological inhibitors of each pathway step, siRNA knockdown of CDP, EMSA/DNA binding assays, ELISA for CCL3/4 protein\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors combined with siRNA knockdown establishing direct transcriptional link; single lab\",\n      \"pmids\": [\"15498767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tristetraprolin (TTP) directly binds CCL3 mRNA via conserved AU-rich elements and destabilizes it. TTP-/- macrophages produce elevated LPS-induced CCL3; CCL3-/-/TTP-/- double knockout mice show significant improvement in inflammatory arthritis and reduced aortic plaque formation compared with TTP-/- single knockouts.\",\n      \"method\": \"TTP-bound mRNA screen in activated macrophages, RIP/RNA binding assay, TTP-/- and CCL3-/-/TTP-/- double-KO mice, histological and functional assessments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct RNA-binding identification plus genetic epistasis via double-KO rescuing multiple in vivo disease phenotypes\",\n      \"pmids\": [\"21784977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL3 (MIP-1α) acts as a growth, survival, and chemotactic factor in multiple myeloma (MM) cells by activating both the AKT/PKB and the MAPK/ERK pathways; PI3-K inhibitors blocked AKT activation but not ERK activation, indicating no cross-talk between these two CCL3-dependent signaling branches in MM cells.\",\n      \"method\": \"Chemotaxis assay, cell proliferation/survival assays, pathway inhibitors (PI3-K inhibitors), Western blot for pAKT and pERK\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays and pharmacological dissection of signaling branches; single lab\",\n      \"pmids\": [\"12506012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The CCL3-CCR5 axis regulates intratumoral accumulation of macrophages, granulocytes, and fibroblasts and promotes neovascularization in lung metastasis. CCL3 stimulates macrophages to express MMP-9 and fibroblasts to express HGF via CCR5. CCL3-/- and CCR5-/- mice showed markedly reduced lung metastasis foci, reduced intratumoral leukocyte/fibroblast accumulation, and reduced MMP-9 and HGF expression.\",\n      \"method\": \"CCL3-/- and CCR5-/- mice, bone marrow chimera, in vitro CCL3 stimulation assays, immunohistochemistry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dual-gene KO with chimeric mouse models and in vitro mechanistic validation; multiple readouts\",\n      \"pmids\": [\"18941229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL3 (MIP-1α) released by activated endothelial cells binds preferentially to the apical surface of cytokine-activated human brain microvessel endothelial cells (HBMEC). In resting HBMEC, CCL3 is minimally expressed, but TNF-α, IL-1β, LPS and TNF-α/IFN-γ significantly upregulate its expression and release; the polarized apical surface presentation of CCL3 after cytokine treatment was established by immunoelectron microscopy.\",\n      \"method\": \"Primary HBMEC culture, ELISA, immunocytochemistry, immunoelectron microscopy\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct localization by immunoelectron microscopy with cytokine induction; single lab\",\n      \"pmids\": [\"20047691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL3 (MIP-1α) expression is downstream of FGFR3 and RAS-MAPK signaling in multiple myeloma. FGFR3 inhibitors and FGFR3-specific siRNA downregulated MIP-1α promoter activity, gene expression, and protein secretion; ERK1 inhibition also downregulated MIP-1α in cells with RAS mutations, placing CCL3 downstream of FGFR3→RAS→MAPK.\",\n      \"method\": \"FGFR3 kinase inhibitors, FGFR3 siRNA, FGF ligand stimulation, promoter assays, gene expression profiling, ERK1 inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (3 inhibitors + siRNA + ligand stimulation) defining pathway position; single lab\",\n      \"pmids\": [\"16849642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL3 (MIP-1α) and its receptor CCR1 are required for hepatocellular carcinoma progression. CCR1- and CCL3-deficient mice showed markedly reduced tumor foci and reduced tumor angiogenesis, associated with decreased intratumoral Kupffer cell accumulation and reduced MMP-9 gene expression.\",\n      \"method\": \"CCR1-/- and CCL3-/- mice in DEN-induced and HBs antigen splenocyte transfer HCC models, immunohistochemistry, gene expression analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two-gene KO in two independent HCC models with multiple readouts; single lab\",\n      \"pmids\": [\"16284949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL3 (via CCR1) mediates the thoracic radiation-induced lung inflammation and fibrosis. Irradiated CCL3-/- mice or CCR1-/- mice did not develop lung inflammation, fibrosis, or decline in lung function seen in wild-type mice; pharmacologic CCR1 inhibition also prevented these outcomes. By contrast, CCR5-/- mice were not protected.\",\n      \"method\": \"CCL3-/-, CCR1-/-, CCR5-/- mice, pharmacological CCR1 inhibitor, hydroxyproline assay, flow cytometry, lung function measurement\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic dissection with three KO lines plus pharmacological confirmation, selective for CCR1 over CCR5\",\n      \"pmids\": [\"20870892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL3 deficiency (MIP-1α-/-) attenuates T cell-mediated hepatitis by reducing recruitment of CCR1-expressing CD4+ T cells to the liver, with consequent reduction in hepatic IFN-γ production. Pharmacological dual CCR1/CCR5 blockade with met-RANTES also reduced hepatic injury and CD4+ T cell liver infiltration.\",\n      \"method\": \"CCL3-/- mice, con A hepatitis model, flow cytometry, met-RANTES pharmacological blockade, biochemical and histological liver injury assessment\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice combined with pharmacological blockade defining CCL3-CCR1 pathway in T cell hepatitis\",\n      \"pmids\": [\"15368307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CCL3 selectively mobilizes mature NK (mNK) cells from the bone marrow into the periphery by acting through CCR1, and inhibits CXCL12-mediated mNK cell retention in vitro. pNK cells migrate to CCL3 only after CXCL12 priming, while immature NK cells (iNK) lack CCR1 and do not respond to CCL3.\",\n      \"method\": \"Mouse bone marrow NK cell subset characterization, in vitro chemotaxis assays, in vivo CCL3 and CXCR4 antagonist (AMD-3100) administration, flow cytometry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro combination; single lab\",\n      \"pmids\": [\"18227348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CCL3/SCI/MIP-1α inhibits proliferation of primitive hematopoietic stem cell progenitors (CFU-S day 12 and day 8) in vitro in a dose-dependent manner and reduces CFU-S compartment cycling in vivo, providing myeloprotection after chemotherapy as shown by improved neutrophil recovery kinetics.\",\n      \"method\": \"In vitro CFU-S colony-forming assay, in vivo mouse bone marrow regeneration models, neutrophil recovery kinetics\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro dose-response plus in vivo myeloprotection models with functional neutrophil recovery endpoint; replicated by multiple labs\",\n      \"pmids\": [\"1571537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Recombinant LD78 protein in solution forms soluble heterogeneous multimeric complexes (100–>250 kDa) from an 8-kDa monomer; defined homogeneous monomer and tetramer forms can be prepared and display distinct conformational properties, as determined by analytical ultracentrifugation, circular dichroism, and fluorescence spectroscopy.\",\n      \"method\": \"Analytical ultracentrifugation, circular dichroism, fluorescence spectroscopy\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — biophysical characterization of oligomeric states with multiple methods but in single study\",\n      \"pmids\": [\"8499450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"MIP-1α (LD78/SCI) inhibits proliferation of clonogenic epidermal keratinocytes in vitro, and MIP-1α mRNA is present in epidermal Langerhans cells but not in keratinocytes, suggesting a paracrine growth inhibitory role in keratopoiesis.\",\n      \"method\": \"In vitro clonogenic keratinocyte proliferation assay with recombinant MIP-1α, Northern blot/in situ hybridization for mRNA localization\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — in vitro inhibition assay plus cell-type-specific mRNA localization; single lab\",\n      \"pmids\": [\"8345211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"MIP-1α modulates spermatogenesis stage-specifically: it increases DNA synthesis in primitive type A2-4 spermatogonia and premeiotic cells, while inhibiting DNA synthesis in more differentiated intermediate and type B spermatogonia. An anti-MIP-1α antibody cross-reacts with a 15 kDa protein expressed at every spermatogenic stage.\",\n      \"method\": \"In vitro stage-specific DNA synthesis assay with recombinant MIP-1α, immunohistochemistry with anti-MIP-1α antibody\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vitro functional assay + immunolocalization; single lab, single study\",\n      \"pmids\": [\"8187954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MIP-1α (LD78) promotes osteoclastogenesis on calcified matrices in the absence of osteotropic hormones and is expressed by osteoblasts at bone-remodeling sites and eosinophilic myelocytes in human bone marrow, suggesting a role in bone remodeling.\",\n      \"method\": \"In situ hybridization, immunohistochemistry with monoclonal antibody, in vitro osteoclastogenesis on calcified matrices\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — in vitro osteoclastogenesis assay plus direct localization; single lab\",\n      \"pmids\": [\"9121122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In EBV-infected B cells (LCLs), LMP1-mediated JNK activation is responsible for upregulation of CCL3 and CCL4. Autocrine CCL3 and CCL4 are required for LCL survival and proliferation, as shRNA knockdown or neutralizing antibodies against CCL3/CCL4 suppressed cell proliferation and induced apoptosis.\",\n      \"method\": \"Cytokine antibody arrays, JNK inhibitor, shRNA knockdown, neutralizing antibodies, apoptosis assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway defined via inhibitor plus shRNA/antibody intervention with functional survival readout; single lab\",\n      \"pmids\": [\"23760235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL3 promotes VEGF-A expression in osteosarcoma cells via activation of JNK, ERK, and p38 MAPK pathways, with each pathway inhibitor abolishing CCL3-induced VEGF-A upregulation. CCL3 also reduces miR-374b expression, and miR-374b mimic reverses CCL3-promoted VEGF-A expression and angiogenesis in vitro and in vivo.\",\n      \"method\": \"Kinase inhibitors (JNK, ERK, p38), miR-374b mimic transfection, endothelial progenitor cell migration/tube formation assays, mouse xenograft model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — multiple pathway inhibitors plus miRNA rescue experiment with in vitro and in vivo validation; single lab\",\n      \"pmids\": [\"26713602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Elevated CCL3 in the leukemic environment suppresses erythropoiesis via CCR1-mediated p38 phosphorylation and subsequent GATA1 downregulation. CCR1 antagonist partially recovered erythroid colony yield; knockdown of CCL3 attenuated leukemic progression and alleviated anemia.\",\n      \"method\": \"Cytokine array, colony-forming cell assay, CCR1 antagonist, Western blot for p38/GATA1, CCL3 knockdown in AML mouse model\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic signaling dissection (CCR1→p38→GATA1) with pharmacological and genetic perturbation; single lab\",\n      \"pmids\": [\"27109512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Intracerebroventricularly administered CCL3 (MIP-1α) induces fever that is independent of LPS signaling cascade (PFPF, ET-1) but is dependent on CRF: a non-selective CRF receptor antagonist (α-helical CRF9-41) reduced CCL3-induced fever, while bosentan (ET receptor antagonist) did not. Anti-CCL3 antibody abolished CCL3-induced fever but did not affect LPS-induced fever.\",\n      \"method\": \"Intracerebroventricular injection, pharmacological antagonists (anti-CCL3 antibody, bosentan, α-helical CRF9-41), temperature measurement in rats\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection defining CCL3 pyrogenic mechanism; single lab, single study\",\n      \"pmids\": [\"19285486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCL3 stimulates human chondrosarcoma cell migration and MMP-2 expression via CCR5, AMPK, p38 MAPK, and NF-κB signaling pathways. Inhibitors or inactive mutants of AMPK, p38, and NF-κB abolished CCL3-induced MMP-2 expression and migration; MMP-2 siRNA or inhibitor blocked CCL3-induced migration.\",\n      \"method\": \"CCR5 knockdown, pharmacological inhibitors and dominant-negative mutants of AMPK/p38/NF-κB, MMP-2 siRNA, migration assay\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors + siRNA; single lab\",\n      \"pmids\": [\"24047437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CCL3-/- mice exhibit loss of mature myeloid populations in peripheral blood while myeloid progenitors and HSPCs are increased, with unchanged bone marrow microenvironmental cell populations. This demonstrates that CCL3 promotes myeloid lineage differentiation and regulates HSPC pool size independently of the bone marrow microenvironment.\",\n      \"method\": \"CCL3-/- mice, flow cytometry of hematopoietic compartments, bone marrow microenvironment analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO phenotype with defined cellular readouts; single lab\",\n      \"pmids\": [\"30279500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Docetaxel (DTX) induces CCL3 expression in macrophages and cancer cells by relieving CREB-mediated repression of the CCL3 promoter via ROS accumulation. DTX-induced CCL3 then promotes proinflammatory macrophage polarization via the CCL3-CCR5-p38/IRF5 signaling pathway, which subsequently facilitates macrophage phagocytosis of breast cancer cells.\",\n      \"method\": \"Ccl3-KO mice, macrophage depletion, RNA sequencing, CREB inhibitor, ROS measurement, CCR5 and p38/IRF5 pathway analysis, phagocytosis assay\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and pharmacological approaches defining the mechanism; single lab\",\n      \"pmids\": [\"35613826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"H. pylori infection stimulates macrophages to secrete CCL3 via the JAK1-STAT1 pathway (with STAT1 identified as a direct transcription factor for the CCL3 promoter by ChIP assay). CCL3 then damages gastric epithelial tight junctions by activating P38 phosphorylation; neutralizing anti-CCL3 antibody or CCL3 receptor inhibitor restored tight junction integrity.\",\n      \"method\": \"RT-qPCR, Western blot, ELISA, dual-luciferase reporter assay, chromatin immunoprecipitation (ChIP), transepithelial electrical resistance, immunofluorescence, in vivo mouse CCL3 injection\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP identifying direct TF binding + functional pathway (JAK1-STAT1→CCL3→P38→tight junction disruption) with rescue experiments; single lab\",\n      \"pmids\": [\"38730482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In cartilage endplate chondrocytes under abnormal mechanical stress, Hippo signaling activation suppresses YAP1, which in turn de-represses the CCL3 promoter, leading to CCL3 release that recruits osteoclasts and promotes endplate remodeling. YAP1 overexpression (via AAV5) inhibited CCL3 transcription by blocking its promoter, reversing endplate remodeling and disc degeneration.\",\n      \"method\": \"Transcriptome sequencing, Yap1 conditional knockout and overexpression (AAV5), lumbar spine instability mouse model, in vitro stress experiments\",\n      \"journal\": \"Bone research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic manipulation (KO + OE) with direct promoter blocking and in vivo rescue; single lab\",\n      \"pmids\": [\"38816384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCL3 in the aging bone marrow microenvironment promotes adipogenic differentiation of BMSCs via activation of STAT3 → C/EBPα, with a positive feedback loop where C/EBPα directly binds the CCL3 promoter (facilitated by DNA hypomethylation) to further activate CCL3 expression. CCL3 also inhibits osteogenic differentiation by blocking β-catenin activity through ERK-activated DKK1 upregulation. In vivo CCL3 deletion or neutralization rescued bone loss and marrow adiposity in aged mice.\",\n      \"method\": \"Antibody array, Ccl3-/- mice, in vivo neutralizing antibody treatment, BMSC differentiation assays, ChIP, Western blot for STAT3/C/EBPα/β-catenin/DKK1/ERK\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion + neutralization rescue + mechanistic dissection with ChIP and multiple signaling nodes; single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"36378535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCL3 and its receptor CCR5 are required for maintenance (but not initiation) of chronic pelvic pain in experimental autoimmune prostatitis (EAP). CCL3-/- mice showed resistance to maintenance of pelvic pain while CCR5-/- mice did not, indicating CCL3 acts through a CCR5-independent mechanism for pain maintenance.\",\n      \"method\": \"CCL3-/-, CCR5-/-, CCR2-/- mice, neutralizing antibodies, bone marrow reconstitution, von Frey and thermal pain assays\",\n      \"journal\": \"American journal of physiology - regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple KO mice with pain behavioral endpoints; single lab\",\n      \"pmids\": [\"22814670\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL3 (MIP-1α/LD78α) is a CC chemokine that signals through G protein-coupled receptors CCR1 and CCR5 to exert chemotaxis of monocytes, T cells, neutrophils, and NK cells; it forms polydisperse rod-shaped double-helical polymers (polymerization buries receptor-binding sites and protects the chemokine from proteolytic degradation by IDE, which selectively cleaves monomers); its mRNA is post-transcriptionally regulated by the ARE-binding protein tristetraprolin; it is transcriptionally controlled downstream of FGFR3/RAS-MAPK and Hippo/YAP1 signaling, with STAT1 as a direct promoter-binding transcription factor; neutrophil-derived serine proteases (cathepsin G, elastase, proteinase 3) cleave and inactivate it at defined sites; and functionally it suppresses hematopoietic stem cell and keratinocyte proliferation, promotes osteoclastogenesis, drives viral-induced inflammation, mediates HIV suppression via competitive CCR5 occupancy (with the LD78β isoform showing far greater potency due to a Pro-2 residue), and activates downstream PI3K/AKT and MAPK/ERK cell survival/migration cascades in multiple cell types.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL3 (MIP-1α/LD78α) is a secreted CC chemokine that orchestrates leukocyte recruitment and inflammatory responses by signaling through the G protein-coupled receptors CCR1 and CCR5 [#2, #11, #15]. It was identified as a major CD8+ T cell-derived HIV-suppressive factor, blocking HIV-1, HIV-2, and SIV replication, and its non-allelic isoform LD78β shows markedly greater receptor affinity and HIV-suppressive potency owing to a proline at position 2 [#0, #5]. In vivo, CCL3 is required for normal inflammatory responses to viral infection and drives a broad spectrum of pathologies through receptor-restricted signaling: CCR1-dependent recruitment of leukocytes underlies radiation-induced lung fibrosis, T cell-mediated hepatitis, hepatocellular carcinoma progression, and NK-cell mobilization from bone marrow, whereas CCR5-dependent signaling promotes lung metastasis and macrophage/fibroblast accumulation [#1, #11, #14, #15, #16, #17]. Downstream of its receptors CCL3 activates PI3K/AKT and MAPK/ERK survival and migration cascades, as well as p38, JNK, NF-κB, and AMPK branches that drive MMP and VEGF-A expression in tumor cells and tight-junction disruption in gastric epithelium [#10, #24, #27, #30]. CCL3 exerts cell-type-specific effects on proliferation and differentiation, suppressing hematopoietic progenitor and keratinocyte proliferation while promoting myeloid differentiation, osteoclastogenesis, and—in the aging marrow—adipogenic over osteogenic BMSC differentiation [#18, #20, #22, #28, #32]. Structurally, CCL3 self-associates into rod-shaped double-helical oligomers stabilized by glycosaminoglycan binding; polymerization buries receptor-binding sites and protects against degradation, while insulin-degrading enzyme selectively cleaves monomers and neutrophil serine proteases (cathepsin G, elastase, proteinase 3) inactivate it at defined sites [#3, #4, #6, #19]. Its expression is tightly controlled transcriptionally—downstream of FGFR3/RAS-MAPK and Hippo/YAP1 signaling, with STAT1 binding the promoter directly—and post-transcriptionally through tristetraprolin-mediated destabilization of its AU-rich mRNA [#9, #13, #30, #31].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established the first non-chemotactic functional role of CCL3 as a negative regulator of progenitor cell proliferation, defining it as more than an inflammatory mediator.\",\n      \"evidence\": \"In vitro CFU-S colony assays and in vivo myeloprotection after chemotherapy; in vitro clonogenic keratinocyte assays with mRNA localization to Langerhans cells\",\n      \"pmids\": [\"1571537\", \"8345211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor and signaling mechanism of growth inhibition not defined\", \"Whether inhibition is direct or paracrine-mediated unresolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Identified CCR1 as a functional GPCR for CCL3 and began characterizing its self-association behavior and promoter regulation, anchoring receptor signaling and gene control.\",\n      \"evidence\": \"Stable transfectants with cAMP/calcium readouts; analytical ultracentrifugation/CD/fluorescence on oligomeric states; promoter deletion, EMSA, and footprinting\",\n      \"pmids\": [\"7505609\", \"8499450\", \"8474441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of oligomerization not yet resolved\", \"Functional consequence of multimeric vs monomeric forms unknown at this stage\", \"Identity of ICK-1 binding factors not molecularly defined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined CCL3 as a major HIV-suppressive factor and demonstrated its non-redundant requirement for antiviral inflammatory responses in vivo.\",\n      \"evidence\": \"Protein purification, neutralizing antibody blockade, recombinant inhibition of HIV/SIV; MIP-1α knockout mice in Coxsackievirus and influenza models\",\n      \"pmids\": [\"8525373\", \"7667639\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor competition mechanism of HIV suppression not yet defined\", \"Cell types mediating in vivo antiviral effect not fully resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved why CCL3 isoforms differ functionally by pinpointing a single Pro-2 residue in LD78β that drives enhanced CCR5/D6 binding and HIV suppression.\",\n      \"evidence\": \"Receptor binding affinity assays, Pro-2 site-directed mutagenesis, HIV-1 suppression assays\",\n      \"pmids\": [\"10364178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Pro-2-conferred affinity not determined\", \"Physiological relevance of isoform ratio in vivo unaddressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated receptor-specific roles for CCL3 in tissue pathology and dissected a novel transcriptional repression pathway, separating CCR1- and CCR5-driven effects.\",\n      \"evidence\": \"CCR1-/- and CCL3-/- mice in HCC and Con A hepatitis models with met-RANTES blockade; PGE2 pathway dissection (EP2→cAMP→EPAC→PI3K→PKB→GSK3→CDP) with siRNA\",\n      \"pmids\": [\"16284949\", \"15368307\", \"15498767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCR1 effects are direct on tumor cells or via recruited leukocytes not fully resolved\", \"Generality of CDP repression across cell types unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established CCL3-CCR5 as a driver of the metastatic tumor microenvironment and CCL3-CCR1 as a regulator of NK cell trafficking, broadening its physiological reach.\",\n      \"evidence\": \"CCL3-/- and CCR5-/- mice with bone marrow chimeras and MMP-9/HGF induction assays; NK cell subset chemotaxis and in vivo mobilization with AMD-3100\",\n      \"pmids\": [\"18941229\", \"18227348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of CXCL12 priming of NK responsiveness not molecularly defined\", \"Relative contributions of stromal vs hematopoietic CCL3 sources incompletely mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Solved the structural and biophysical logic of CCL3 self-assembly, showing polymerization regulates receptor accessibility and proteolytic stability.\",\n      \"evidence\": \"X-ray crystallography, SEC/AUC, mutagenesis, monocyte arrest assays, IDE knockdown; endothelial polarized presentation by immunoelectron microscopy\",\n      \"pmids\": [\"20959807\", \"20047691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of polymer vs monomer equilibrium not quantified\", \"How polymer disassembly is regulated physiologically unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined post-transcriptional control of CCL3 by tristetraprolin and proved its causal role in inflammatory disease via genetic epistasis.\",\n      \"evidence\": \"TTP-bound mRNA screen and RIP in macrophages; CCL3-/-/TTP-/- double-KO rescue of arthritis and atherosclerosis\",\n      \"pmids\": [\"21784977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other ARE-binding proteins acting on CCL3 mRNA not surveyed\", \"Tissue specificity of TTP-mediated control not detailed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Refined the structural understanding of CCL3 oligomers in complex with glycosaminoglycans, revealing a distinct GAG-binding groove and conformational plasticity of the N-terminus.\",\n      \"evidence\": \"X-ray crystallography of GAG-bound oligomers, biophysical analyses, mutagenesis\",\n      \"pmids\": [\"27091995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo role of GAG-anchored oligomers in haptotactic gradients not directly tested\", \"Link between N-terminal conformation and receptor signaling not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Clarified the hematopoietic function of CCL3 by showing it promotes myeloid lineage differentiation and constrains the HSPC pool independently of the bone marrow niche.\",\n      \"evidence\": \"CCL3-/- mice with flow cytometry of hematopoietic compartments and microenvironment analysis\",\n      \"pmids\": [\"30279500\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-intrinsic vs extrinsic mechanism of differentiation promotion unresolved\", \"Receptor mediating this effect not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified direct transcriptional control of CCL3 by STAT1 and by Hippo/YAP1, completing a picture of multilayered upstream regulation linked to epithelial and skeletal pathology.\",\n      \"evidence\": \"ChIP of STAT1 at the CCL3 promoter with JAK1-STAT1→CCL3→p38 tight-junction disruption rescue; Yap1 conditional KO/AAV5 overexpression with promoter blocking in disc degeneration model\",\n      \"pmids\": [\"38730482\", \"38816384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between STAT1, YAP1, FGFR3/RAS, and CDP at the promoter not integrated\", \"Context determining which upstream input dominates not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the structural state of CCL3 (monomer, oligomer, GAG-bound polymer) is dynamically tuned in vivo to bias CCR1 versus CCR5 engagement and select among its many context-specific outcomes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo measurement linking oligomeric state to receptor choice\", \"Determinants of CCR1 vs CCR5 selectivity in a given tissue undefined\", \"Unified model integrating proteolysis, polymerization, and transcriptional control absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 5, 11, 15]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 10, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 11, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 10, 27, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 14, 15, 24, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR1\", \"CCR5\", \"ZFP36\", \"IDE\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}